Brokerages Set Teleflex Incorporated (NYSE:TFX) Target Price at $151.80

Shares of Teleflex Incorporated (NYSE:TFX) have been given an average recommendation of “Hold” by the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $151.80.

A number of brokerages recently issued reports on TFX. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a report on Wednesday, June 24th. Wells Fargo & Company raised their target price on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Zacks Research upgraded Teleflex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Piper Sandler reissued an “overweight” rating and issued a $169.00 price objective (up from $160.00) on shares of Teleflex in a research note on Friday, August 7th. Finally, Mizuho boosted their target price on Teleflex from $140.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th.

Teleflex Stock Up 0.1%

TFX stock opened at $138.99 on Monday. Teleflex has a fifty-two week low of $100.18 and a fifty-two week high of $145.00. The company’s 50 day moving average price is $132.70 and its 200 day moving average price is $124.88. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.12 and a current ratio of 2.60. The firm has a market capitalization of $5.89 billion, a price-to-earnings ratio of -5.97, a PEG ratio of 0.93 and a beta of 0.81.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The business had revenue of $570.33 million during the quarter, compared to analysts’ expectations of $559.59 million. During the same period in the previous year, the company earned $3.73 EPS. The company’s revenue for the quarter was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, equities research analysts anticipate that Teleflex will post 7.26 EPS for the current fiscal year.

Teleflex Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Friday, August 14th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. Teleflex’s dividend payout ratio (DPR) is -5.84%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Kelleher Financial Advisors purchased a new position in Teleflex during the 2nd quarter valued at about $25,000. Banque Cantonale Vaudoise boosted its stake in shares of Teleflex by 82.5% during the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 113 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after buying an additional 113 shares in the last quarter. Allworth Financial LP purchased a new stake in Teleflex in the 2nd quarter worth approximately $44,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Teleflex in the fourth quarter valued at $45,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.